Valerie S. LeBleu, Ph.D.
Affiliations: | 2009 | Harvard University, Cambridge, MA, United States |
Area:
Cell BiologyGoogle:
"Valerie LeBleu"Parents
Sign in to add mentor| Raghu Kalluri | grad student | 2009 | Harvard | |
| (The pathobiochemistry of Alport syndrome and mechanism of cell-based therapy.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| LeBleu VS, Kanasaki K, Lovisa S, et al. (2024) Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome. Life Science Alliance. 7 |
| Laklai H, Miroshnikova YA, Pickup MW, et al. (2023) Author Correction: Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nature Medicine |
| Kugeratski FG, LeBleu VS, Dowlatshahi DP, et al. (2023) Engineered immunomodulatory extracellular vesicles derived from epithelial cells acquire capacity for positive and negative T cell co-stimulation in cancer and autoimmunity. Biorxiv : the Preprint Server For Biology |
| Mahadevan KK, LeBleu VS, Ramirez EV, et al. (2023) Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8 T cells. Developmental Cell |
| Mahadevan KK, McAndrews KM, LeBleu VS, et al. (2023) KRAS inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8 T cells. Cancer Cell |
| LeBleu VS, Dai J, Tsutakawa S, et al. (2023) Identification of unique α4 chain structure and conserved antiangiogenic activity of α3NC1 type IV collagen in zebrafish. Developmental Dynamics : An Official Publication of the American Association of Anatomists |
| Mahadevan KK, McAndrews KM, LeBleu VS, et al. (2023) Oncogenic Kras specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 T cells dependent manner. Biorxiv : the Preprint Server For Biology |
| Haltom AR, Hassen WE, Hensel J, et al. (2022) Engineered exosomes targeting MYC reverse the proneural-mesenchymal transition and extend survival of glioblastoma. Extracellular Vesicle. 1 |
| Melo SA, Luecke LB, Kahlert C, et al. (2022) Author Correction: Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature |
| LeBleu VS. (2022) Plasticity Enables Cooperation among Heterogeneous Cancer Cell Populations to Support Metastatic Fitness. Cancer Research. 82: 1870-1871 |